A citation-based method for searching scientific literature

Carmen W H Chan, Bernard M H Law, Winnie K W So, Ka Ming Chow, Mary M Y Waye. J Cancer Res Clin Oncol 2020
Times Cited: 12







List of co-cited articles
39 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Meredith M Regan, Brian Leyland-Jones, Mark Bouzyk, Olivia Pagani, Weining Tang, Roswitha Kammler, Patrizia Dell'orto, Maria Olivia Biasi, Beat Thürlimann, Maria B Lyng,[...]. J Natl Cancer Inst 2012
238
25


RNA expression of cytochrome P450 in breast cancer patients.
Radka Vaclavikova, Miluse Hubackova, Jana Stribrna-Sarmanova, Roman Kodet, Marcela Mrhalova, Jan Novotny, Ivan Gut, Pavel Soucek. Anticancer Res 2007
25
16



Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Madhu S Singh, Prudence A Francis, Michael Michael. Breast 2011
47
16

Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.
A Rahman, K R Korzekwa, J Grogan, F J Gonzalez, J W Harris. Cancer Res 1994
350
16

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Jean E Abraham, Mel J Maranian, Kristy E Driver, Radka Platte, Bolot Kalmyrzaev, Caroline Baynes, Craig Luccarini, Mitul Shah, Susan Ingle, David Greenberg,[...]. Breast Cancer Res 2010
72
16

CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance.
V G Martinez, R O'Connor, Y Liang, M Clynes. Br J Cancer 2008
44
16

Variation in CYP2A6 Activity and Personalized Medicine.
Julie-Anne Tanner, Rachel F Tyndale. J Pers Med 2017
66
16

Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
Jun Zhou, Qiang Wen, Sai-Fei Li, Yun-Fei Zhang, Na Gao, Xin Tian, Yan Fang, Jie Gao, Ming-Zhu Cui, Xiao-Pei He,[...]. Oncotarget 2016
42
16

Cytochrome P450 and anticancer drugs.
Ken-ichi Fujita. Curr Drug Metab 2006
59
16

Cytochrome P450 pharmacogenetics and cancer.
C Rodriguez-Antona, M Ingelman-Sundberg. Oncogene 2006
392
16

Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance.
M C McFadyen, H L McLeod, F C Jackson, W T Melvin, J Doehmer, G I Murray. Biochem Pharmacol 2001
129
16

The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
Bo Lan, Fei Ma, Xiaoyu Zhai, Qiao Li, Shanshan Chen, Jiayu Wang, Ying Fan, Yang Luo, Ruigang Cai, Peng Yuan,[...]. Int J Cancer 2018
18
16

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Matthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, Matthias Schwab, Michael Province, Michelle Whirl-Carrillo, W Fraser Symmans, Howard L McLeod, Mark J Ratain, Hitoshi Zembutsu,[...]. Clin Pharmacol Ther 2018
156
16

PharmGKB summary: tamoxifen pathway, pharmacokinetics.
Daniel J Klein, Caroline F Thorn, Zeruesenay Desta, David A Flockhart, Russ B Altman, Teri E Klein. Pharmacogenet Genomics 2013
60
16

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
James M Rae, Suzy Drury, Daniel F Hayes, Vered Stearns, Jacklyn N Thibert, Ben P Haynes, Janine Salter, Ivana Sestak, Jack Cuzick, Mitch Dowsett. J Natl Cancer Inst 2012
184
16

Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.
Hyeong-Seok Lim, Han Ju Lee, Keun Seok Lee, Eun Sook Lee, In-Jin Jang, Jungsil Ro. J Clin Oncol 2007
184
16

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Yan Jin, Zeruesenay Desta, Vered Stearns, Bryan Ward, Herbert Ho, Kyung-Hoon Lee, Todd Skaar, Anna Maria Storniolo, Lang Li, Adjei Araba,[...]. J Natl Cancer Inst 2005
674
16


Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Pia Wegman, Linda Vainikka, Olle Stål, Bo Nordenskjöld, Lambert Skoog, Lars-Erik Rutqvist, Sten Wingren. Breast Cancer Res 2005
171
16

Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.
Patrick Neven, Lynn Jongen, Anneleen Lintermans, Kathleen Van Asten, Chantal Blomme, Diether Lambrechts, An Poppe, Hans Wildiers, Anne-Sophie Dieudonné, Olivier Brouckaert,[...]. Clin Cancer Res 2018
40
16

Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Sung-Hsin Kuo, Shi-Yi Yang, San-Lin You, Huang-Chun Lien, Ching-Hung Lin, Po-Han Lin, Chiun-Sheng Huang. Oncotarget 2017
25
16

Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
Yenny, Sonar S Panigoro, Denni J Purwanto, Adi Hidayat, Melva Louisa, Rizka Andalusia, Rianto Setiabudy. Endocr Metab Immune Disord Drug Targets 2019
4
50

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Peter Fox, Rosemary L Balleine, Clara Lee, Bo Gao, Bavanthi Balakrishnar, Alexander M Menzies, Shang Heng Yeap, Sayed Sahanawaz Ali, Val Gebski, Pamela Provan,[...]. Clin Cancer Res 2016
50
16

Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
T E Mürdter, W Schroth, L Bacchus-Gerybadze, S Winter, G Heinkele, W Simon, P A Fasching, T Fehm, M Eichelbaum, M Schwab,[...]. Clin Pharmacol Ther 2011
200
16

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
Harriet Johansson, Kathryn P Gray, Olivia Pagani, Meredith M Regan, Giuseppe Viale, Valentina Aristarco, Debora Macis, Antonella Puccio, Susanne Roux, Rudolf Maibach,[...]. Breast Cancer Res 2016
17
16

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.
Wei He, Felix Grassmann, Mikael Eriksson, Erik Eliasson, Sara Margolin, Linda Thorén, Per Hall, Kamila Czene. J Clin Oncol 2020
20
16

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
Matthew P Goetz, James M Rae, Vera J Suman, Stephanie L Safgren, Matthew M Ames, Daniel W Visscher, Carol Reynolds, Fergus J Couch, Wilma L Lingle, David A Flockhart,[...]. J Clin Oncol 2005
572
16

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Pia Wegman, Sauli Elingarami, John Carstensen, Olle Stål, Bo Nordenskjöld, Sten Wingren. Breast Cancer Res 2007
209
16

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Werner Schroth, Matthew P Goetz, Ute Hamann, Peter A Fasching, Marcus Schmidt, Stefan Winter, Peter Fritz, Wolfgang Simon, Vera J Suman, Matthew M Ames,[...]. JAMA 2009
381
16

The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.
L K Teh, N I Mohamed, M Z Salleh, M Rohaizak, N S Shahrun, J J Saladina, J K S Shia, H Roslan, S Sood, T S Rajoo,[...]. AAPS J 2012
51
16

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Werner Schroth, Lydia Antoniadou, Peter Fritz, Matthias Schwab, Thomas Muerdter, Ulrich M Zanger, Wolfgang Simon, Michel Eichelbaum, Hiltrud Brauch. J Clin Oncol 2007
327
16

Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study.
Hitoshi Zembutsu, Seigo Nakamura, Sadako Akashi-Tanaka, Takashi Kuwayama, Chie Watanabe, Tomoko Takamaru, Hiroyuki Takei, Takashi Ishikawa, Kana Miyahara, Hiroshi Matsumoto,[...]. Clin Cancer Res 2017
24
16

Personalizing aromatase inhibitor therapy in patients with breast cancer.
Issam S Hamadeh, Jai N Patel, Stephanie Rusin, Antoinette R Tan. Cancer Treat Rev 2018
16
16

Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention.
Vasilis P Androutsopoulos, Aristidis M Tsatsakis, Demetrios A Spandidos. BMC Cancer 2009
255
16

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Alan S Coates, Aparna Keshaviah, Beat Thürlimann, Henning Mouridsen, Louis Mauriac, John F Forbes, Robert Paridaens, Monica Castiglione-Gertsch, Richard D Gelber, Marco Colleoni,[...]. J Clin Oncol 2007
675
16

Abiraterone and increased survival in metastatic prostate cancer.
Johann S de Bono, Christopher J Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N Chi, Robert J Jones, Oscar B Goodman, Fred Saad,[...]. N Engl J Med 2011
16

Postvaccination Fever Response Rates in Children Derived Using the Fever Coach Mobile App: A Retrospective Observational Study.
Sang Hyun Ahn, Jooho Zhiang, Hyery Kim, Seyun Chang, Jaewon Shin, Myeongchan Kim, Yura Lee, Jae-Ho Lee, Yu Rang Park. JMIR Mhealth Uhealth 2019
5
20

A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial.
Marco Egbring, Elmira Far, Malgorzata Roos, Michael Dietrich, Mathis Brauchbar, Gerd A Kullak-Ublick, Andreas Trojan. J Med Internet Res 2016
51
8

Knowledge, attitude, and practice towards pharmacogenomics among hospital pharmacists in Thailand.
Narainrit Karuna, Pramote Tragulpiankit, Surakameth Mahasirimongkol, Supatat Chumnumwat. Pharmacogenet Genomics 2020
12
8

Game on: The gamification of the pharmacy classroom.
Leah Sera, Erin Wheeler. Curr Pharm Teach Learn 2017
23
8


Gamification of a Mobile Applications Lecture in a Pharmacy Course.
Emily P Jones, Christopher S Wisniewski. Med Ref Serv Q 2019
5
20

Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
Stefania Morganti, Paolo Tarantino, Emanuela Ferraro, Paolo D'Amico, Bruno Achutti Duso, Giuseppe Curigliano. Adv Exp Med Biol 2019
59
8

Pharmacogenomics: An evolving clinical tool for precision medicine.
Jennifer K Hockings, Amy L Pasternak, Angelika L Erwin, Neil T Mason, Charis Eng, J Kevin Hicks. Cleve Clin J Med 2020
13
8

Opportunities for pharmacists to integrate pharmacogenomics into clinical practice.
Yan-Ting Wang, Man Yee Merl, Jun Yang, Zhi-Xiang Zhu, Guo-Hui Li. Pharmacogenomics J 2020
16
8

How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.
Richard J Marrero, Emily J Cicali, Meghan J Arwood, Elizabeth Eddy, David DeRemer, Brian H Ramnaraign, Karen C Daily, Dennie Jones, Kelsey J Cook, Larisa H Cavallari,[...]. Clin Pharmacol Ther 2020
17
8

TControl: A mobile app to follow up tobacco-quitting patients.
Marc Pifarré, Adrián Carrera, Jordi Vilaplana, Josep Cuadrado, Sara Solsona, Francesc Abella, Francesc Solsona, Rui Alves. Comput Methods Programs Biomed 2017
4
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.